Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer biotech buy­out

It’s tak­en 7 years, but Eli Lil­ly is promis­ing to fi­nal­ly start ham­mer­ing the small and af­flu­ent PD-(L)1 club with a “dis­rup­tive” pric­ing strat­e­gy for their check­point ther­a­py al­lied with Chi­na’s In­novent.

Lil­ly in-li­censed glob­al rights to sin­til­imab a year ago, build­ing on the Chi­na al­liance they have with In­novent. That cost the phar­ma gi­ant $200 mil­lion in cash up­front, which they plan to cap­i­tal­ize on now with a long-await­ed plan to bust up the high-price mar­ket in lung can­cer and oth­er can­cers that have cre­at­ed a mar­ket worth tens of bil­lions of dol­lars.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN